Doxorubicin Exposure Causes Subacute Cardiac Atrophy Dependent on the Striated Muscle-Specific Ubiquitin Ligase MuRF1.
Animals
Antineoplastic Agents
/ administration & dosage
Cardiotoxicity
/ diagnostic imaging
Disease Models, Animal
Dose-Response Relationship, Drug
Doxorubicin
/ administration & dosage
Echocardiography
Gene Expression
Heart
/ diagnostic imaging
Heart Failure
/ chemically induced
Humans
Injections, Intraperitoneal
Magnetic Resonance Imaging
Male
Mice
Mice, Inbred C57BL
Muscle Proteins
/ genetics
Muscular Atrophy
/ chemically induced
Myocardium
/ metabolism
Myocytes, Cardiac
/ drug effects
Tripartite Motif Proteins
/ genetics
Ubiquitin-Protein Ligases
/ genetics
Up-Regulation
anthracycline
atrophy
cardiotoxicity
doxorubicin
heart failure
mice
ubiquitin
Journal
Circulation. Heart failure
ISSN: 1941-3297
Titre abrégé: Circ Heart Fail
Pays: United States
ID NLM: 101479941
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
entrez:
16
3
2019
pubmed:
16
3
2019
medline:
28
1
2020
Statut:
ppublish
Résumé
Background Anthracycline chemotherapeutics, such as doxorubicin, are used widely in the treatment of numerous malignancies. The primary dose-limiting adverse effect of anthracyclines is cardiotoxicity that often presents as heart failure due to dilated cardiomyopathy years after anthracycline exposure. Recent data from animal studies indicate that anthracyclines cause cardiac atrophy. The timing of onset and underlying mechanisms are not well defined, and the relevance of these findings to human disease is unclear. Methods and Results Wild-type mice were sacrificed 1 week after intraperitoneal administration of doxorubicin (1-25 mg/kg), revealing a dose-dependent decrease in cardiac mass ( R
Identifiants
pubmed: 30871347
doi: 10.1161/CIRCHEARTFAILURE.118.005234
pmc: PMC6422170
mid: NIHMS1520435
doi:
Substances chimiques
Antineoplastic Agents
0
Muscle Proteins
0
Tripartite Motif Proteins
0
Doxorubicin
80168379AG
Trim63 protein, mouse
EC 2.3.2.27
Ubiquitin-Protein Ligases
EC 2.3.2.27
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e005234Subventions
Organisme : NHLBI NIH HHS
ID : K08 HL096836
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA012197
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL140067
Pays : United States
Commentaires et corrections
Type : CommentIn
Références
Cancer Cell. 2017 Jan 9;31(1):142-156
pubmed: 28017613
Circ Res. 2013 Mar 29;112(7):1046-58
pubmed: 23538275
J Clin Oncol. 1998 Jan;16(1):27-34
pubmed: 9440719
Cardiovasc Toxicol. 2007;7(2):114-21
pubmed: 17652815
Circulation. 2006 Jan 31;113(4):535-43
pubmed: 16449733
Am J Cardiol. 2012 Dec 1;110(11):1679-86
pubmed: 22917553
Circ Heart Fail. 2015 Jan;8(1):98-108
pubmed: 25420486
Ann Oncol. 2010 Jul;21(7):1492-9
pubmed: 20007997
Eur J Cancer. 2016 Apr;57:58-67
pubmed: 26882087
Cardiovasc Res. 2013 Jun 1;98(3):381-90
pubmed: 23455548
Circulation. 2015 Jun 2;131(22):1981-8
pubmed: 25948538
Cardiovasc Res. 2017 Dec 1;113(14):1708-1718
pubmed: 29016754
Am J Physiol Heart Circ Physiol. 2009 Apr;296(4):H997-H1006
pubmed: 19168726
Circ Heart Fail. 2018 Jul;11(7):e004560
pubmed: 29991488
Proc Natl Acad Sci U S A. 2004 Dec 28;101(52):18135-40
pubmed: 15601779
J Cardiovasc Magn Reson. 2017 Aug 2;19(1):59
pubmed: 28768517
Nat Med. 2012 Nov;18(11):1639-42
pubmed: 23104132
Cardiovasc Res. 2008 Jul 1;79(1):89-96
pubmed: 18346979
Heart. 2015 Dec;101(23):1874-80
pubmed: 26416836
J Mol Med (Berl). 2017 Mar;95(3):239-248
pubmed: 27933370
Cancer Treat Rep. 1978 Jun;62(6):955-61
pubmed: 352510
JACC Cardiovasc Imaging. 2018 Aug;11(8):1045-1055
pubmed: 30092965
Circ Heart Fail. 2016 Jan;9(1):e002661
pubmed: 26747861
Exp Biol Med (Maywood). 2012 Feb;237(2):219-26
pubmed: 22328594
Ann Hematol. 2015 Dec;94(12):2043-53
pubmed: 26385388
J Physiol. 2003 Aug 15;551(Pt 1):33-48
pubmed: 12844509
Thromb Res. 2018 May 17;167:128-134
pubmed: 29843086
J Basic Clin Pharm. 2016 Mar;7(2):27-31
pubmed: 27057123
Cell Biol Toxicol. 2007 Jan;23(1):27-37
pubmed: 17041747
Proc Natl Acad Sci U S A. 2016 Nov 15;113(46):13144-13149
pubmed: 27799559
J Cachexia Sarcopenia Muscle. 2017 Dec;8(6):939-953
pubmed: 28887874
Am J Physiol Endocrinol Metab. 2014 Sep 15;307(6):E469-84
pubmed: 25096180
Cardiovasc Res. 2010 Jan 15;85(2):357-66
pubmed: 19850579
JACC Cardiovasc Imaging. 2013 Aug;6(8):877-85
pubmed: 23643285
J Appl Physiol (1985). 2014 Aug 1;117(3):223-30
pubmed: 24947024
J Physiol. 2015 Apr 15;593(8):2017-36
pubmed: 25643692
Circ Res. 2007 Mar 2;100(4):456-9
pubmed: 17272810
Cardiovasc Res. 2011 May 1;90(2):243-50
pubmed: 21354996
Pharmacogenomics. 2013 Jan;14(2):205-13
pubmed: 23327580
J Mol Cell Cardiol. 2006 Sep;41(3):389-405
pubmed: 16879835
J Mol Cell Cardiol. 2012 Jun;52(6):1213-25
pubmed: 22465037
Am J Physiol Endocrinol Metab. 2016 Sep 1;311(3):E594-604
pubmed: 27382036
J Am Heart Assoc. 2013 Apr 08;2(2):e000016
pubmed: 23568341
J Card Fail. 2016 Jun;22(6):439-48
pubmed: 27109619
J Clin Invest. 2007 Sep;117(9):2486-95
pubmed: 17786241
J Mol Cell Cardiol. 2014 Jun;71:43-53
pubmed: 24262338
J Am Coll Cardiol. 2000 Aug;36(2):517-22
pubmed: 10933366
Eur J Cancer. 2018 May;94:126-137
pubmed: 29567630
Cardiology. 2011;118(4):256-9
pubmed: 21757899
J Am Coll Cardiol. 2018 May 22;71(20):2281-2290
pubmed: 29540327
Am J Physiol Heart Circ Physiol. 2016 Feb 15;310(4):H466-77
pubmed: 26718971
Eur J Pharmacol. 2011 Nov 30;670(2-3):541-53
pubmed: 21946105